Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial (ADEPT) (ADEPT)

Recruiting
14 years or above
Female
Phase N/A
1 Location

Brief description of study

This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth 35 weeks randomized to either 162 mg aspirin or 81 mg aspirin initiated between 10 and 15 weeks gestation and continued through 36 weeks gestation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pregnancy
  • Age: 14 years or above
  • Gender: Female
Updated on 02 Apr 2026. Study ID: 25-0784

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center